Treatment of hepatosplenic schistosomiasis mansoni with niridazole: relationships among liver function, effective dose, and side effects.
D000293:Adolescent; D000328:Adult; D000871:Anthelmintics / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001774:Blood Chemical Analysis; D002648:Child; D003097:Collateral Circulation; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism / Q000503:physiopathology; D008107:Liver Diseases / Q000188:drug therapy*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011172:Portography; D011605:Psychoses, Substance-Induced / Q000209:etiology; D012552:Schistosomiasis / Q000188:drug therapy*; D012640:Seizures / Q000139:chemically induced; D013158:Splenic Diseases / Q000188:drug therapy*; D013844:Thiazoles / Q000627:therapeutic use*
D000871:Anthelmintics; D007093:Imidazoles; D013844:Thiazoles